版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
IPECActivitiesandExcipientRegulationintheUnitedStatesPresentationtoSFDADavidR.SchonekerDirectorofGlobalRegulatoryAffairsOctober13,20041OutlineIPECBackgroundIPECGuidelinesandInitiativesExcipient&ColorantRegulationintheU.S.ExcipientMasterFilesExcipientQualificationProcessPharmacopeialHarmonizationPre-mixedExcipientsSUPAC&PostApprovalChanges2WhatisIPEC?3WhatisIPEC?4Colorcon’sInvolvementwithIPECColorconwasafoundingmemberofIPECColorconisafullmemberinIPECAmericas,IPECEurope,andJPECColorconactivelyparticipatesinthefollowingIPECCommittees:ExecutiveCompendialReview–HarmonizationWorkingGroupsGMPExcipientQualificationRegulatoryAffairsManyCommitteesarechairedbyColorconpersonnel5IPECMission6BuildingBridgeswithRegulators
IPECisactivelymeetingwithhighleveldirectorsatFDA,EMEA,MHLW,USP,PhEur,andJP/JPEtodiscussmanytopicsrelatedtoexcipientsRegulatoryRepresentativesroutinelyparticipateinIPECprojectsasadvisorsIPECprovidestechnicalassistanceandpracticalexperience7ExcipientGMPsintheU.S.U.S.FD&CActstatesthatcomponentsofdrugs(ie;excipients)shouldbemadeusing“appropriate”GMPsThereisnoactualregulationwhichdefineswhatisthe“appropriate”levelofGMPforpharmaceuticalexcipientsFDAdoesNOTroutinelyinspectexcipientmanufacturers;only“forcause”8ExcipientGMPsintheU.S.9IPECExcipientGMP’s10IPECExcipientGMP’s11PublishedIPEC-AmericasGuidelines
12IPECInitiatives13IPECInitiativesDevelopingGuidelinesforExcipientQualificationIncludesboththeUser’sandMaker’sperspectiveDevelopmentofStandardQuestionnairetemplatesThirdPartySupplierAssessment(IPEA)IPEAprovidesassessmentsofexcipientmanufacturingfacilitiesvs.IPECGMPIPEAAudits()14CurrentIPEAAuditReportsReportsReportNumberExcipientChemical/
CompendiaNameManufacturerLocationExcipientTradeNameEQ-01Alcohol,USPEquistarIllinois,USAEthylAlcoholEQ-02Alcohol,USP:denaturing&packagingEquistarNewJersey,USADenaturing&packagingPendingHydroxypropylatedStarchNFPendingPendingPendingPendingCarrageenanNFPendingPendingPendingCPK-01XanthanGumNFCPKelcoOklahoma,USAXantural180NS-01DisodiumSuccinateHexahydrateNipponShokbaiHimeji,JapanSS-50PQ-01SulfuricAcidNFProductosQuimicosNeuvoLeon,MexicoSulfuricAcidSE-01DisodiumSuccinateHydrateShivaEnterprisesPune,IndiaSodiumSuccinateHydratePendingMagnesiumSilicateNFPendingUSAPendingCL-01SodiumHydroxideNFCantonLaboratoriesVadodara,IndiaSodiumHydroxide15UseofExcipientsinNDA’s
intheU.S.FD&CActstatesthatexcipients(otherthancolors)mustmeetUSP/NFrequirementsifamonographexistsUSP/NFexcipientsdonotrequiresubmissionofsignificantqualityinformationwithNDA’s.However,functionalityinformationmaybenecessarybasedontheapplication16UseofExcipientsinNDA’s
intheU.S.17
U.S.GenericApplicationsForU.S.genericdrugapplications,allingredientsneedtobelistedintheFDA’sInactiveIngredientDatabase(formerlyknownastheInactiveIngredientGuideorIIG)ThelevelsofuseofeachexcipientinthedosageformmustbebelowlevelsexperiencedinpreviouslyapproveddrugsIfnot,safetydatamaybeneeded18
U.S.GenericApplications1920GlobalCOLORANTRegulationsForPharmaceuticalsUnitedStates-21CFR(Parts70-82)Europe-ECDirectives78/25/EEC and81/464/EECJapan-MinisterialOrdinanceNo.30(August
31,1966),JP,JPE,JPED,PrecedentListWHO-JECFARequirementsIndividualCountriesmayhaveuniquerequirementsandrestrictionsbasedonlocalrequirements21OneColorForTheWorld:
GlobalFormulationProblemsListofacceptablecolorsvariesSpecificationsaredifferentforthesamecolorantsColorsandspecificationsfornutritionalsupplementsvs.pharmaceuticalsaresometimesdifferentUserestrictionsmayapplyandmayvaryTheseissuescauseonlyafewcolorstobeavailableforinternationalformulations….22KeyColorsUsedInGlobalPharmaceuticalsFD&CBlue#1FD&CYellow#6TitaniumDioxideRedIronOxideYellowIronOxideBlackIronOxide23DesiredGlobalColorRegulationsCurrently,thereisnoharmonizationprocessforcolorsEachcountrymaintainstheirownlistsofapprovedcolorswhichcreatesglobaldevelopmentproblemsShouldbebasedprimarilyonsafetyUseofJECFAfoodcolorlistasaglobalstandardwouldbeveryhelpful!!!24DrugMasterFiles25USDMFFacts(J.Clark,FDA,2003)
March31,2003:16481DMFsonfile“Inactive”presumablymeansnoLOA/annualreport recentlysubmitted26USDMFFilings,2002(J.Clark,FDA,2003)DMFs DMFs/yearAll 585TypeII 358TypeIII 172TypeIV 51TypeV 427DrugMasterFileRequirements
Specifiedin1989guidancedocumentDMFTypesI.Manufacturingsite,facilitiesII.Drugsubstance,intermediate,drug
productIII.PackagingmaterialIV.Excipient,colorant,flavor,etc.V.FDAAcceptedReferenceInformation28TypeIVDMFInformationRequirements29IPECProposals:
Global“ExcipientMasterFiles”ExcipientMasterFile,astandardformatforsubmittinginformationIPECguidancepublished2004UnderconsiderationatFDASimplifyfilingprocessApplicabletoallexcipientsStandardformatandinformationrequirementsGlobalsubmissionsSimplifyreviewprocessStandardformatandinformationrequirements30ExcipientMasterFiles:ConsistentwithCTDSubmissionsWouldcontainallinformationrequiredinSectionP4ofCTDP4.1Specifications(Q6B)P4.2AnalyticalProcedures(Q2A,Q6B)P4.3ValidationofAnalyticalProcedures(Q2A,Q2B,Q6B)P4.4JustificationofSpecifications(Q3C,Q6B)P4.5ExcipientsofHumanorAnimalOrigin(Q5A,Q5D,Q6B)P4.6NovelExcipients31ExcipientMasterFileComponents32EMFOrganizationSummariesTechnicalReportsandDataRegionalInfoCoreTechnicalDocumentAdministrativeSection33TheIncreasingVisibilityofExcipients
ImpactoftheHaitiglycerindisasterCounterfeitDrugsandBioterrorismFutureneeds:WideinternationalacceptancetofacilitatethedesignofglobalpharmaceuticalformulationsAssurethatappropriateGMPandqualitystandardsareappliedtothedesignandmanufactureofthesematerialsForregulatoryagenciestogainabetterunderstandingofthepurposeandfunctionalityofexcipientsindrugformulations34Qualificationof
ExcipientSuppliers35SupplierQualification36IPECExcipientQualificationGuidelineCurrentProject37ExcipientQualification
Guideline3839ExcipientQualification
Process-User4041PharmacopeialHarmonization4243HarmonizationofExcipientStandardsPharmacopeiasUsersManufacturersRegulatory44Today’sHarmonizationOutcomes45ChinesePharmacopeiaCantheChinesePharmacopeia(CP)beharmonizedwiththeUSP?CanUSPgradeexcipientsbeusedinChinesedrugapplicationsifaCPmonographexists?ArethereanyGMPrequirementsforexcipientswhichcomplywithChinesePharmacopeiamonographs46ProductFilingInformation
Pre-MixedExcipients47ProductFilingInformation
Pre-mixedExcipientsTypicalinformationRequired:ProductcodenumberListofcomponents(chemicalnamesincludingviscosity/MWinformation)QuantitativepercentagesforeachcomponentGradeofeachcomponent(USP/NF,PhEur,JP/JPE,CFR,FCC,ECDirective,etc.)Evidenceofprioruseofeachcomponentinoralapplicationsatsimilarlevels4849DrugMasterFiles
Pre-mixedExcipients50Post-ApprovalChanges
UnitedStatesGuidanceforIndustry:ChangestoanApprovedNDAorANDA
ComponentandCompositionsectionrefersbacktoSUPAC(ScaleUpandPostApprovalChanges)guidancesSUPACcanbeusedtomakecertainchangesinexcipientlevelsMinorChangesareLevel1-AnnualReport,nopriorapprovalSUPACcoversdeletionofacolororflavorasaLevel1changeSUPACalsoallowsforadditionofanimprintcodeorqualitativechangesinprintinginksasa
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 2026年新能源行業(yè)技術(shù)突破與市場(chǎng)前景創(chuàng)新報(bào)告
- 2026年西安長(zhǎng)安大學(xué)工程設(shè)計(jì)研究院有限公司招聘?jìng)淇碱}庫及答案詳解1套
- 南宮市2025年公開招聘警務(wù)輔助人員的備考題庫及一套答案詳解
- 2025-2030工業(yè)機(jī)器人底座市場(chǎng)競(jìng)爭(zhēng)力分析及未來趨勢(shì)預(yù)測(cè)研究報(bào)告
- 2025至2030中國(guó)工業(yè)傳感器技術(shù)創(chuàng)新與應(yīng)用前景研究報(bào)告
- 2025-2030中國(guó)防水藍(lán)牙揚(yáng)聲器行業(yè)市場(chǎng)發(fā)展趨勢(shì)與前景展望戰(zhàn)略研究報(bào)告
- 2025至2030中國(guó)碳纖維復(fù)合材料軍工領(lǐng)域滲透率提升策略研究報(bào)告
- 2025至2030基因檢測(cè)服務(wù)行業(yè)發(fā)展現(xiàn)狀及消費(fèi)者需求變化與投資策略研究報(bào)告
- 2026年西安華山金屬材料科技有限公司招聘?jìng)淇碱}庫參考答案詳解
- 2026年鹽城經(jīng)濟(jì)技術(shù)開發(fā)區(qū)公開招聘基層醫(yī)療機(jī)構(gòu)專業(yè)技術(shù)人員6人備考題庫及1套參考答案詳解
- 2025年及未來5年中國(guó)三文魚行業(yè)市場(chǎng)前景預(yù)測(cè)及投資戰(zhàn)略研究報(bào)告
- 人工智能在射頻電路中的應(yīng)用-洞察及研究
- (正式版)DB65∕T 3997-2017 《油氣田鉆井固體廢物綜合利用污染控制要求》
- 2024-2025學(xué)年四川省廣元市蒼溪縣九年級(jí)(上)期末數(shù)學(xué)試卷(含答案)
- T-CBDA 82-2024 家裝防水防潮與滲漏修繕技術(shù)規(guī)程
- 基于灰色模型下的經(jīng)濟(jì)發(fā)展生育意愿分析與預(yù)測(cè)
- 腸道屏障修復(fù)研究-洞察及研究
- 審計(jì)數(shù)據(jù)管理辦法
- 2025國(guó)開《中國(guó)古代文學(xué)(下)》形考任務(wù)1234答案
- 研發(fā)公司安全管理制度
- 兒童口腔診療行為管理學(xué)
評(píng)論
0/150
提交評(píng)論